Whole Genome Sequencing (WGS) on IVF Embryos and Individual Patients

Description

This research project aims to utilise recent advances in whole genome sequencing of preimplantation genetic diagnosis embryos to investigate the impact of paternal age on de novo mutation rates in IVF embryos. Embryos that are deemed unsuitable for transfer following preimplantation genetic testing for monogenic/single gene disorders (PGT-M) due to the detection of genetic abnormalities will be utilized for this study. These embryos will undergo re-biopsy, and both the biopsied samples as well as the remaining embryo tissue will be subject to whole genome sequencing. This will allow the assessment of de novo mutation rates based on the paternal age.

Conditions

Fertility Issues, Single-Gene Defects

Study Overview

Study Details

Study overview

This research project aims to utilise recent advances in whole genome sequencing of preimplantation genetic diagnosis embryos to investigate the impact of paternal age on de novo mutation rates in IVF embryos. Embryos that are deemed unsuitable for transfer following preimplantation genetic testing for monogenic/single gene disorders (PGT-M) due to the detection of genetic abnormalities will be utilized for this study. These embryos will undergo re-biopsy, and both the biopsied samples as well as the remaining embryo tissue will be subject to whole genome sequencing. This will allow the assessment of de novo mutation rates based on the paternal age.

Study of the Effect of Paternal Age on de Novo Mutation Rate by Using Whole Genome Sequencing of IVF Embryos

Whole Genome Sequencing (WGS) on IVF Embryos and Individual Patients

Condition
Fertility Issues
Intervention / Treatment

-

Contacts and Locations

New York

Neway Fertility, New York, New York, United States, 10024

Portland

ORM Fertility, Portland, Oregon, United States, 97205

Kirkland

Poma Fertility, Kirkland, Washington, United States, 98034

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

For general information about clinical research, read Learn About Studies.

Eligibility Criteria

  • * Female patients with low ovarian reserve (\< 10 follicles or FSH\>10, AMH \<1).

Ages Eligible for Study

18 Years to 48 Years

Sexes Eligible for Study

ALL

Accepts Healthy Volunteers

No

Collaborators and Investigators

GenEmbryomics Pty. Ltd,

Nicholas Murphy, PhD, PRINCIPAL_INVESTIGATOR, GenEmbryomics Pty. Ltd

Study Record Dates

2024-08